We are monitoring the impact of COVID-19 on Europe Cancer Metabolism Based Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7868
Share on
Share on

Europe Cancer Metabolism Based Therapeutics Market Research Report – Segmented By Therapy, Drug Type, Indication & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 7868
Pages: 145

Europe Cancer Metabolism Based Therapeutics Market Size (2020 to 2025)

The size of the Europe Cancer Metabolism Based Therapeutics Market is projected to grow at a prominent CAGR from 2020 to 2025. With increasing access to health care and the presence of key players, Europe Cancer Metabolism Based Therapeutics Market is growing rapidly.

The hike in this market is driven by several factors, some of which increase the number of people diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, and chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.

Growing access to healthcare and the existence of market key players are propelling the market demand. According to Cancer Research, UK, nearly 3,072 new cases in people are diagnosed with acute myeloid leukemia (AML), and around 2,516 deaths occurred in 2014. An unhealthy diet, physical activity, and exposure of the body to various radiations drive the market growth. The available number of therapies for cancer treatment metabolism is restricted, which in turn provides better growth opportunities for the key players in the region. 71% of the cancer deaths occur mostly in low and middle-income countries, and the number of people who have pancreatic cancer is high, where 53 thousand people are diagnosed with pancreatic cancer. Nearly 43 thousand are undergoing risk for their lives.

The expensive nature of the treatment associated with cancer-based therapeutics may pull back the market in some of the developing countries of the region is restraining the market in the area. The risk of adverse effects related to cancer drugs therapeutics and failure of the treatment would decline the growth of the market. Lack of technologies in advancements and low reimbursement policies hamper the cancer metabolism-based therapeutics market demand in this region.

This research report on the Europe Cancer Metabolism Based Therapeutics Market has been segmented & sub-segmented into the following categories:

By Therapy:

  • Biological Drug Therapies  
  • Targeted Drug Therapies  

By Drug Type:

  • Enasidenib              
  • CPI-613    
  • Other Drugs      

By Indication:

  • Melanoma              
  • Myelodysplastic Syndrome (MDS)
  • Acute Myeloid Leukemia (AML)    
  • Metastatic Renal Cell Carcinoma    
  • Others     

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regional Analysis:

Europe is just behind North America globally and is the second largest in the cancer metabolism-based therapeutics market growth during the analysis period. Factors like growth in the number of cancer patients who are examined every year, consumption of tobacco smoking are impelling the growth in the region. Increasing cancer cases will surge the demand for new therapies to assist aid cancer metabolism circumstances that are accelerating the development of the market in the area.

The UK is anticipated to lead the cancer metabolism-based therapeutics market in the region due to growing research and development towards target-based therapies.

The UK follows Germany in leading the market driven by heredity, chemicals, and urban air pollution. Growing usage of new and latest technologies for treating cancer cells surge the market growth in cancer metabolism-based therapeutics market over the period. Many of the non-profit organizations are coming into the picture in assisting people, and growing knowledge regarding the symptoms and treatment procedures for pancreatic cancer is stimulating the market size in the region.

Some of the prime manufacturers leading the European Cancer Metabolism Based Therapeutics market are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapy                       

                                5.1.1 Introduction           

                                5.1.2 Biological Drug Therapies  

                                5.1.3 Targeted Drug Therapies  

                                5.1.4  Y-o-Y Growth Analysis, By Therapy              

                                5.1.5  Market Attractiveness Analysis, By Therapy            

                                5.1.6  Market Share Analysis, By Therapy             

                5.2 Drug Type                   

                                5.2.1 Introduction           

                                5.2.2 Enasidenib              

                                5.2.3 CPI-613     

                                5.2.4 Other Drugs            

                                5.2.5 Y-o-Y Growth Analysis, By Drug Type           

                                5.2.6 Market Attractiveness Analysis, By Drug Type         

                                5.2.7 Market Share Analysis, By Drug Type          

                5.3 Indication                    

                                5.3.1 Introduction           

                                5.3.2 Melanoma              

                                5.3.3 Myelodyspalstic Syndrome (MDS)

                                5.3.4 Acute Myeloid Leukemia (AML)    

                                5.3.5 Metastatic Renal Cell Carcinoma    

                                5.3.6 Others      

                                5.3.7 Y-o-Y Growth Analysis, By Indication           

                                5.3.8 Market Attractiveness Analysis, By Indication         

                                5.3.9 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapy

                                                6.1.3.3 By Drug Type

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapy

                                                6.1.4.3 By Drug Type

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapy

                                                6.1.5.3 By Drug Type

                                                6.1.5.4 By Indication

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 AstraZeneca                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis                       

                8.3 Celgene                       

                8.4 Rafael Pharmaceuticals                         

                8.5 Cornerstone Pharmaceuticals                            

                8.6 Polaris Group                             

                8.7 Agios Pharmaceuticals                           

                8.8 Taiho Pharmaceuticals                           

                8.9 3-V Biosciences                         

                8.10 Calithera Biosciences                           

                8.11 BERG Health                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapy, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Europe Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  2. Europe Biological Drug Therapies Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe Targeted Drug Therapies   Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  5. Europe Enasidenib         Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe CPI-613 Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe Other Drugs Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)
  9. Europe Melanoma Market, By Region, From 2020 to 2025 (USD Million)
  10. Europe Myelodyspalstic Syndrome (MDS) Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe Acute Myeloid Leukemia (AML) Market, By Region, From 2020 to 2025 (USD Million)
  12. Europe Metastatic Renal Cell Carcinoma Market, By Region, From 2020 to 2025 (USD Million)
  13. Europe Others       Market, By Region, From 2020 to 2025 (USD Million)
  14. U.K. Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  15. U.K. Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  16. U.K. Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)
  17. Germany Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  18. Germany Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  19. Germany Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)
  20. France Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  21. France Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  22. France Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)
  23. Italy Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  24. Italy Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  25. Italy Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)
  26. Spain Cancer Metabolism Based Therapeutics Market, By Therapy, From 2020 to 2025 (USD Million)
  27. Spain Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2020 to 2025 (USD Million)
  28. Spain Cancer Metabolism Based Therapeutics Market, By Indication, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample